Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Non-Current Assets (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Non-Current Assets for 12 consecutive years, with $197000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets fell 95.65% year-over-year to $197000.0, compared with a TTM value of $8.8 million through Sep 2025, down 52.56%, and an annual FY2024 reading of $4.3 million, down 9.68% over the prior year.
  • Non-Current Assets was $197000.0 for Q3 2025 at Arcadia Biosciences, down from $209000.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $19.9 million in Q2 2021 and bottomed at $197000.0 in Q3 2025.
  • Average Non-Current Assets over 5 years is $6.1 million, with a median of $4.4 million recorded in 2022.
  • The sharpest move saw Non-Current Assets surged 70.19% in 2021, then tumbled 95.76% in 2025.
  • Year by year, Non-Current Assets stood at $8.5 million in 2021, then plummeted by 58.69% to $3.5 million in 2022, then soared by 34.31% to $4.7 million in 2023, then dropped by 9.68% to $4.3 million in 2024, then tumbled by 95.39% to $197000.0 in 2025.
  • Business Quant data shows Non-Current Assets for RKDA at $197000.0 in Q3 2025, $209000.0 in Q2 2025, and $4.1 million in Q1 2025.